TRDA

Entrada Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001689375
$6.46 +2.38% $250.8M
Insider Selling Cluster (2 insiders)7 New Institutional Positions7 Institutional Exits
Vol
Market Cap$250.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders50 funds
Inst. Value$169.8M
Inst. Activity7 buys / 7 sells
Insider Activity1B / 8S
Insider Net $-$1.1M
SEC Reports7
Press Releases1
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001689375·Prev Close $6.31

Recent Activity

Jun 10, 2026 SEC
Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders approve
8-K — Impact 2/10
Jun 10, 2026 Insider
Zeiher Bernhardt G was granted 19,000 shares
Director
Jun 10, 2026 Insider
Thistle Mary was granted 19,000 shares
Director
Jun 10, 2026 Insider
Radhakrishnan Maha was granted 19,000 shares
Director
Jun 2, 2026 Press
Entrada Therapeutics announced that an independent DMC recommended dose escalation to 10 mg/kg in Cohort 2 of the ELEVAT
Impact 4/10
May 7, 2026 SEC
Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 b
PRESS-RELEASE — Impact 6/10
May 4, 2026 SEC
Two top executives at Entrada Therapeutics sold a combined $629K in open-market sales over a 7-day window, with Presiden
CLUSTER — Impact 5/10
Inst.
Woodline Partners LP — ADD
215,977 shares ($2.7M)

Price Targets

$18.75 +190.2% upside Strong Buy
Current $6.46 Low $10.00 Median $20.00 High $25.00 4 analysts
$10.00 $25.00

Analyst Ratings

Strong Buy86% buy · 14 analysts
5Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 8, 2026 Guggenheim MAINTAIN Buy → Buy
May 8, 2026 HC Wainwright & Co. DOWNGRADE Buy → Neutral
Apr 6, 2026 Oppenheimer MAINTAIN Outperform → Outperform
Feb 18, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Feb 11, 2026 Guggenheim INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-1.04 ▲ +1.9% $-1.34 — $-0.68 -0% YoY 7
Next Q $-0.94 $-1.18 — $-0.63 11% YoY 7
Current FY $-3.79 ▲ +2.4% $-4.49 — $-2.68 -9% YoY 7
Next FY $-3.26 ▲ +5.4% $-5.08 — $-2.20 14% YoY 6

Latest Reports

NEUTRAL 8-K 2/10
Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders approve
Jun 10, 2026
NEUTRAL Press 4/10
Entrada Therapeutics announced that an independent DMC recommended dose escalation to 10 mg/kg in Cohort 2 of the ELEVAT
Jun 2, 2026
MIXED PRESS-RELEASE 6/10
Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 b
May 7, 2026

Top Institutional Holders

FundValueMove
ROYAL BANK OF CANADA—DOUBLED
BAKER BROS. ADVISORS LP$64.0M—
BlackRock, Inc.$29.8M—
VANGUARD CAPITAL MANAGEMENT LLC$15.9M—
WELLINGTON MANAGEMENT GROUP LLP$13.1M—

Recent Insider Trades

DateInsiderTypeValue
Jun 10, 2026Zeiher BernhardtA$0.00
Jun 10, 2026Thistle MaryA$0.00
Jun 10, 2026Radhakrishnan MahaA$0.00
Jun 10, 2026KIM PETERA$0.00
Jun 10, 2026Chapman GinaA$0.00
50 institutional holders with $169.8M total value (13,457,083 shares) as of 2026-Q1. Top holders: ROYAL, BAKER, BlackRock,.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1ROYAL BANK OF CANADA25$0.000.0%DOUBLED +132.8%
2BAKER BROS. ADVISORS LP5,072,730$64.0M37.7%—
3BlackRock, Inc.2,358,793$29.8M17.5%—
4VANGUARD CAPITAL MANAGEMENT LLC1,256,013$15.9M9.3%—
5WELLINGTON MANAGEMENT GROUP LLP1,034,782$13.1M7.7%—
6STATE STREET CORP533,798$6.7M4.0%—
7DIMENSIONAL FUND ADVISORS LP324,471$4.1M2.4%TRIM -30.7%
8VANGUARD PORTFOLIO MANAGEMENT LLC220,494$2.8M1.6%—
9Woodline Partners LP215,977$2.7M1.6%ADD +52.0%
10CITADEL ADVISORS LLC215,018$2.7M1.6%DOUBLED +234.5%
11CHARLES SCHWAB INVESTMENT MANAGEMENT INC214,751$2.7M1.6%—
12GOLDMAN SACHS GROUP INC212,780$2.7M1.6%—
13RENAISSANCE TECHNOLOGIES LLC202,084$2.6M1.5%TRIM -57.5%
14MORGAN STANLEY176,126$2.2M1.3%TRIM -32.3%
15Nuveen, LLC175,648$2.2M1.3%DOUBLED +211.3%
16VANGUARD FIDUCIARY TRUST CO156,861$2.0M1.2%—
17ROYCE & ASSOCIATES LP120,845$1.5M0.9%TRIM -51.1%
18Trexquant Investment LP82,733$1.0M0.6%TRIM -31.8%
19D. E. Shaw & Co., Inc.79,047$997.6K0.6%—
20MANUFACTURERS LIFE INSURANCE COMPANY, THE70,656$891.7K0.5%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
Woodline Partners LPADD142,110215,977+52.0%$2.7M2026-Q1
MORGAN STANLEYTRIM260,251176,126-32.3%$2.2M2026-Q1
Nuveen, LLCDOUBLED56,416175,648+211.3%$2.2M2026-Q1
ROYCE & ASSOCIATES LPTRIM247,147120,845-51.1%$1.5M2026-Q1
Trexquant Investment LPTRIM121,28082,733-31.8%$1.0M2026-Q1
MARSHALL WACE, LLPDOUBLED20,65753,764+160.3%$678.5K2026-Q1
TD ASSET MANAGEMENT INCADD37,78853,588+41.8%$676.3K2026-Q1
BANK OF AMERICA CORP /DE/TRIM65,97939,212-40.6%$494.9K2026-Q1
HSBC HOLDINGS PLCADD20,83338,137+83.1%$471.8K2026-Q1
Brevan Howard Capital Management LPTRIM47,96726,349-45.1%$332.5K2026-Q1
CANADA PENSION PLAN INVESTMENT BOARDTRIM25,60017,700-30.9%$223.4K2026-Q1
ExodusPoint Capital Management, LPTRIM37,43012,067-67.8%$152.3K2026-Q1
CWM, LLCDOUBLED2,1146,788+221.1%$85.7K2026-Q1
PRICE T ROWE ASSOCIATES INC /MD/ADD327,423526,043+60.7%$6.6K2026-Q1
DIMENSIONAL FUND ADVISORS LPTRIM394,279273,378-30.7%$2.8M2025-Q4
RENAISSANCE TECHNOLOGIES LLCTRIM594,300252,635-57.5%$2.6M2025-Q4
ROYCE & ASSOCIATES LPTRIM345,507247,147-28.5%$2.5M2025-Q4
BANK OF AMERICA CORP /DE/TRIM126,44865,979-47.8%$678.3K2025-Q4
TWO SIGMA INVESTMENTS, LPTRIM93,19449,302-47.1%$506.8K2025-Q4
Invesco Ltd.ADD29,07541,033+41.1%$421.8K2025-Q4
WELLS FARGO & COMPANY/MNADD21,61632,163+48.8%$330.6K2025-Q4
MetLife Investment Management, LLCDOUBLED7,16017,802+148.6%$183.0K2025-Q4
FMR LLCTRIM31,94616,822-47.3%$172.9K2025-Q4
Russell Investments Group, Ltd.ADD8,80811,571+31.4%$118.9K2025-Q4
Mirae Asset Global Investments Co., Ltd.ADD1,4711,857+26.2%$19.1K2025-Q4
10 unique insiders with 32 transactions. Net insider value: -$1.1M ($29.3K bought, $1.2M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 10, 2026Zeiher Bernhardt GDirectorAWARD19,000——
Jun 10, 2026Thistle MaryDirectorAWARD19,000——
Jun 10, 2026Radhakrishnan MahaDirectorAWARD19,000——
Jun 10, 2026KIM PETER SDirectorAWARD19,000——
Jun 10, 2026Chapman GinaDirectorAWARD19,000——
Jun 10, 2026PARMAR KUSHDirectorAWARD19,000——
May 20, 2026Zeiher Bernhardt GDirectorBUY5,000$5.86$29.3K
May 4, 2026Dowden Nathan JPresident & COOEXERCISE15,000$1.74$26.1K
May 4, 2026Dowden Nathan JPresident & COOSELL15,000$15.33$230.0K
May 4, 2026Sethuraman NatarajanPresident, Research & Develop.SELL25,907$15.39$398.8K
Apr 1, 2026WENTWORTH KORY JAMESChief Financial OfficerSELL2,500$12.95$32.4K
Mar 10, 2026Dowden Nathan JPresident & COOSELL11,894$13.05$155.2K
Mar 10, 2026WENTWORTH KORY JAMESChief Financial OfficerSELL11,388$13.02$148.2K
Mar 9, 2026Dowden Nathan JPresident & COOSELL3,116$13.02$40.6K
Mar 9, 2026WENTWORTH KORY JAMESChief Financial OfficerSELL5,089$13.00$66.2K
Mar 4, 2026WENTWORTH KORY JAMESChief Financial OfficerSELL7,988$12.25$97.9K
Mar 3, 2026Doshi DipalCEOTAX W/H19,181$11.76$225.5K
Mar 3, 2026Sethuraman NatarajanPresident, Research & Develop.TAX W/H7,577$11.76$89.1K
Mar 3, 2026Dowden Nathan JPresident & COOTAX W/H14,038$11.76$165.0K
Mar 3, 2026WENTWORTH KORY JAMESChief Financial OfficerTAX W/H5,712$11.76$67.2K
Mar 2, 2026Dowden Nathan JPresident & COOTAX W/H7,223$11.66$84.2K
Mar 2, 2026Doshi DipalCEOTAX W/H9,869$11.66$115.1K
Mar 2, 2026Sethuraman NatarajanPresident, Research & Develop.TAX W/H3,898$11.66$45.4K
Mar 2, 2026WENTWORTH KORY JAMESChief Financial OfficerTAX W/H2,939$11.66$34.3K
Mar 1, 2026Doshi DipalCEOAWARD139,400——
Mar 1, 2026Doshi DipalCEOAWARD208,000——
Mar 1, 2026Sethuraman NatarajanPresident, Research & Develop.AWARD83,200——
Mar 1, 2026Sethuraman NatarajanPresident, Research & Develop.AWARD55,800——
Mar 1, 2026Dowden Nathan JPresident & COOAWARD55,800——
Mar 1, 2026Dowden Nathan JPresident & COOAWARD83,200——
Mar 1, 2026WENTWORTH KORY JAMESChief Financial OfficerAWARD44,600——
Mar 1, 2026WENTWORTH KORY JAMESChief Financial OfficerAWARD66,600——
7 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 4 neutral. Avg impact: 3.9/10.
NEUTRAL 8-K 2/10
Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders.
Jun 10, 2026
MIXED PRESS-RELEASE 6/10
Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating conse
May 7, 2026
BEARISH CLUSTER 5/10
Two top executives at Entrada Therapeutics sold a combined $629K in open-market sales over a 7-day w
May 4, 2026
NEUTRAL 144 2/10
Officer Nathan Dowden filed Form 144 to sell 15,000 shares (approx. $217,500) under a 10b5-1 trading
May 4, 2026
NEUTRAL DEFA14A 3/10
Entrada Therapeutics is holding a shareholder meeting to vote on the election of directors, approval
Apr 24, 2026
NEUTRAL CLUSTER 3/10
Entrada Therapeutics President & COO Nathan J. Dowden sold a total of 15,010 shares in the past week
Mar 11, 2026
BEARISH 8-K 6/10
Entrada Therapeutics reported financial results for Q4 and full year 2025, showing a significant dec
Feb 26, 2026
NEUTRAL 4/10
Entrada Therapeutics announced that an independent DMC recommended dose escalation to 10 mg/kg in Co
Jun 2, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 5 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$18.75 mean target +190.2% upside Strong Buy (1.25)
$10.00 Low $25.00 High
MetricValue
Current Price$6.46
Target Low$10.00
Target Mean$18.75
Target Median$20.00
Target High$25.00
# Analysts4
RecommendationStrong Buy (1.25)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-1.04 $-1.34 $-0.68 -0.3% +1.9% 3↑ 3↓ $0.0B 14.6% 7
Next Q
2026-09-30
 $-0.94 $-1.18 $-0.63 11.5% +0.2% 2↑ 4↓ $0.0B 332.7% 7
Current FY
2026-12-31
 $-3.79 $-4.49 $-2.68 -9.3% +2.4% 4↑ 3↓ $0.0B -41.0% 7
Next FY
2027-12-31
 $-3.26 $-5.08 $-2.20 14.2% +5.4% 3↑ 3↓ $0.0B 98.9% 6

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-1.043
7d ago$-1.060+0.017
30d ago$-1.063+0.020
60d ago$-1.063+0.020
90d ago$-1.068+0.025
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 8, 2026 Guggenheim MAINTAIN Buy Buy
May 8, 2026 HC Wainwright & Co. DOWNGRADE Buy Neutral
Apr 6, 2026 Oppenheimer MAINTAIN Outperform Outperform
Feb 18, 2026 HC Wainwright & Co. REITERATE Buy Buy
Feb 11, 2026 Guggenheim INITIATE — Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20265720086%
May 1, 20265810093%
Apr 1, 20265710092%
Mar 1, 20265710092%
Feb 1, 20264710092%
Jan 1, 20263710091%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 2, 2026
fda
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
An independent safety Data Monitoring Committee recommends the initiation of Cohort 2 in Entrada Therapeutics’ ELEVATE-45-201 study.
Jun 1, 2026
other
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4).
May 7, 2026
earnings
Entrada Therapeutics Reports First Quarter 2026 Financial Results
Entrada Therapeutics reports financial results for the first quarter ended March 31, 2026, and highlights recent business updates.
May 7, 2026
earnings_calendar
TRDA Q1 2026 Earnings Before Market Open — 2026-05-07
May 6, 2026
other
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 202
May 6, 2026
earnings_calendar
TRDA Q1 2026 Earnings Before Market Open — 2026-05-06
Mar 3, 2026
short_interest
FTD: TRDA — 54,878 shares ($0.6M) failed to deliver
Settlement: 20260303, Price: $11.68, FTD Value: $640,975.04, ENTRADA THERAPEUTICS INC COM (
Mar 2, 2026
other
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4).